Alterity Therapeutics has raised A$40 million through a two-tranche placement to advance ATH434, their lead compound showing promising results in Multiple System Atrophy treatment.
Maxim Group analyst Jason McCarthy has increased Alterity Therapeutics' price target to $12 from $8, maintaining a Buy rating following Phase 2 trial results of ATH434 in early-stage multiple system atrophy.
The FDA is set to decide on Biogen and Eisai's Leqembi for monthly intravenous maintenance in early Alzheimer's disease, potentially improving patient convenience.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.